Literature DB >> 17447554

Evaluation of the reproductive effects of tamoxifen citrate in partial and full life-cycle studies using fathead minnows (Pimephales promelas).

Tim D Williams1, John E Caunter, Adam D Lillicrap, Thomas H Hutchinson, Edward G Gillings, Stephen Duffell.   

Abstract

Laboratory studies were conducted to investigate potential adverse effects on development, growth, reproduction and biomarker responses (vitellogenin [VTG] and gonad histology) in fathead minnows (Pimephales promelas) exposed to tamoxifen citrate. Based on the results of a partial life cycle study (nominal [mean measured] concentrations ranged from 0.18 [0.11] to 18 [15.74] microg/L), a 284-d fish full life-cycle (FFLC) flow-through study was conducted using newly fertilized embryos (<24 h postfertilization) exposed to nominal (mean measured) concentrations of 14C-tamoxifen citrate that ranged from 0.01 (0.007) to 5.12 (4.08) microg/L. Triethylene glycol (2.0 microl/L) was used as a solvent carrier, with 17beta-estradiol (E2) as a positive control (nominal 0.1 microg/L). Among the biomarkers measured, significant effects on VTG and gonad histology were observed, although these results required care in their interpretation. Among important population-relevant endpoints, no effects on reproduction were observed at nominal concentrations < or = 5.12 microg/L. Effects on growth (length and weight) were observed in some treatments; however, some of these showed irregular concentration-response relationships, which made interpretation uncertain, or were deemed transient in nature (e.g., reduction in growth of F1 28-d posthatch larval fish at nominal concentrations of 0.08, 0.64, and 5.12 microg/L) and judged not to be biologically significant. Interpretation of results from fish chronic studies is challenging and frequently calls for scientific judgement about statistical and biological significance and what constitutes an adverse effect. Using the principles used in mammalian toxicology studies, data from partial and FFLC studies were evaluated from both statistical and biological perspectives in order to determine no-observed-adverse effect concentrations (expressed as (adverse)NOEC) for use in environmental risk assessment. Careful consideration of both biological and statistical outcomes from these studies suggested overall (adverse)NOEC concentration and lowest-observed-effect concentration ((adverse)LOEC) values for tamoxifen citrate of 5.12 microg/L and 5.6 microg/L, respectively.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17447554     DOI: 10.1897/05-646r1.1

Source DB:  PubMed          Journal:  Environ Toxicol Chem        ISSN: 0730-7268            Impact factor:   3.742


  5 in total

Review 1.  Leveraging existing data for prioritization of the ecological risks of human and veterinary pharmaceuticals to aquatic organisms.

Authors:  Carlie A LaLone; Jason P Berninger; Daniel L Villeneuve; Gerald T Ankley
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-11-19       Impact factor: 6.237

2.  Effects of tamoxifen on autosomal genes regulating ovary maintenance in adult mice.

Authors:  Mingxi Yu; Wei Liu; Jingyun Wang; Junwen Qin; Yongan Wang; Yu Wang
Journal:  Environ Sci Pollut Res Int       Date:  2015-08-26       Impact factor: 4.223

3.  Implementing ecopharmacovigilance in practice: challenges and potential opportunities.

Authors:  Gisela Holm; Jason R Snape; Richard Murray-Smith; John Talbot; David Taylor; Pernilla Sörme
Journal:  Drug Saf       Date:  2013-07       Impact factor: 5.606

4.  The read-across hypothesis and environmental risk assessment of pharmaceuticals.

Authors:  Mariann Rand-Weaver; Luigi Margiotta-Casaluci; Alpa Patel; Grace H Panter; Stewart F Owen; John P Sumpter
Journal:  Environ Sci Technol       Date:  2013-09-30       Impact factor: 9.028

Review 5.  Historical control data for the interpretation of ecotoxicity data: are we missing a trick?

Authors:  Amy C Brooks; Manousos Foudoulakis; Hanna S Schuster; James R Wheeler
Journal:  Ecotoxicology       Date:  2019-11-06       Impact factor: 2.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.